A practical reference on research peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Tryptamines: N-methyltryptamine (NMT) (isomer of AMT) and methylisopropyltryptamine (MiPT) (isomer of DET) Methoxytryptamines: 4-MeO-DMT (isomer of 5-MeO-DMT) and 5-MeO-DPT (isomer of 5-MeO-DiPT) Hydroxytryptamines: 6-HO-DMT and 7-HO-DMT (both isomers of psilocin (4-HO-DMT)) Phenethylamines: Scalines: escaline (isomer of TMA) 2Cs: 2C-G (isomer of 2C-E and DOM) Amphetamines: DOx TMA-2 (2,4,5-TMA) (isomer of TMA), Aleph-2 (isomer of 2C-T-4), and Aleph-4 (isomer of 2C-T-7) 4Cs: Ariadne (isomer of DOET) MDxx: MBDB (isomer of MDEA Others: TMA-6 (2,4,6-TMA) (isomer of TMA) Others have not been explicitly noted by the United States DEA but may also be considered. Examples include the DET isomers MPT and MiPT and the LSD isomers MiPLA and LAMPA, among others.
=== Symmetry breaking === Theories for the origin of homochirality in the molecules of life can be classified as deterministic or based on chance depending on their proposed mechanism. If there is a relationship between cause and effect – that is, a specific chiral field or influence causing the mirror symmetry breaking – the theory is classified as deterministic; otherwise it is classified as a theory based on chance (in the sense of randomness) mechanisms.
=== Adverse effects === Whether naltrexone causes dysphoria, depression, anhedonia, or other aversive effects has been studied and reviewed. In early studies of opioid-abstinent individuals, acute and short-term administration of naltrexone was reported to produce a variety of aversive effects including fatigue, loss of energy, sleepiness, mild dysphoria, depression, lightheadedness, faintness, confusion, nausea, gastrointestinal disturbances, sweating, and occasional derealization. However, these studies were small, often uncontrolled, and used subjective means of assessing side effects. Most subsequent longer-term studies of naltrexone for indications like alcohol or opioid dependence have not reported dysphoria or depression with naltrexone in most individuals. According to one source:
=== Drying === Once the gelation is completed, the liquid surrounding the silica network is carefully removed and replaced with air, while keeping the aerogel intact. It is crucial that the gel is dried in such a way as to minimize the surface tension within the pores of the solid network. This is typically accomplished through supercritical fluid extraction using supercritical carbon dioxide (scCO2) or freeze-drying.This section briefly describes and compares the processing strategies of supercritical drying and freeze-drying. Gels where the liquid is allowed to evaporate at a natural rate are known as xerogels (i. e. are not aerogels). As the liquid evaporates in such manner, forces caused by surface tensions of the liquid-solid interfaces are enough to destroy the fragile gel network. As a result, xerogels cannot achieve the high porosities and instead peak at lower porosities and exhibit large amounts of shrinkage after drying. To avoid the collapse of fibers during slow solvent evaporation and reduce surface tensions of the liquid-solid interfaces, aerogels can be formed by lyophilization (freeze-drying). Depending on the concentration of the fibers and the temperature to freeze the material, the properties such as porosity of the final aerogel will be affected. In 1931, to develop the first aerogels, Kistler used a process known as supercritical drying which avoids a direct phase change.
Sources: en.wikipedia.org
The first flight of the US version, designated XP-51B took place in November 1942, but the USAAF had become so interested in the Merlin Mustang project that an initial contract for 400 aircraft was placed three months beforehand in August. The conversion led to production of the P-51B beginning at NAA's Inglewood, California, plant in June 1943, and P-51s started to become available to the 8th and 9th air forces in the winter of 1943–1944. Conversion to the two-stage supercharged and intercooled Merlin 60 series, over 350 lb (160 kg) heavier than the single-stage Allison, driving a four-bladed Hamilton Standard propeller, required moving the wing slightly forward to correct the aircraft's center of gravity. After the USAAF, in July 1943, directed fighter aircraft manufacturers to maximize internal fuel capacity, NAA calculated the P-51B's center of gravity to be forward enough to include an additional 85 US gal (320 L; 71 imp gal) fuel tank in the fuselage behind the pilot, greatly increasing the aircraft's range over that of the earlier P-51A. NAA incorporated the tank in the production of the P-51B-10, and supplied kits to retrofit it to all existing P-51Bs.
Chromatofocusing is a protein-separation technique that allows resolution of single proteins and other ampholytes from a complex mixture according to differences in their isoelectric point. Chromatofocusing uses ion exchange resins and is typically performed on fast protein liquid chromatography (FPLC) or similar equipment capable of producing continuous buffer gradients, though this is not a requirement. In contrast to typical ion exchange chromatography, where bound molecules are eluted from the resin by increasing the ionic strength of the buffer environment, chromatofocusing elutes bound species by altering the pH of the buffer. This changes the net surface charge of bound molecules, altering their avidity for the resin. As the changing pH of the buffer system traverses the pI of a given molecule, that molecule will elute from the resin as it will no longer possess a net surface charge (a requisite for molecular binding to ion exchange resins). Chromatofocusing is a powerful purification technique with respect to proteins as it can resolve very similar species differing by less than 0.05 pH units that may not separate well, or at all, using traditional ion exchange strategies. A major drawback to this technique is that some proteins will aggregate when they are present at relatively high concentrations and carry no net surface charge. This can cause blockage of the resin, which is highly problematic when using sealed columns of ion exchange resin on FPLC equipment, resulting in pressure buildup and possible equipment failure.
=== Omentin === Omentin is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma omentin-1 levels are significantly decreased in patients with obesity, insulin resistance and diabetes that contribute to the major components of the metabolic syndrome. Insulin resistance contributes to the changes of cholesterol synthesis and absorption as well. However, nothing is known about the relationship between Omentin and metabolic risk factors. So a study were held in Japan comprised 201 Japanese men who underwent annual health check-ups. Plasma Omentin levels were determined by enzyme-linked immunosorbent assay. They divided the subjects into 4 groups according to Omentin levels. A reduction of plasma Omentin levels significantly correlated with an increase in the mean number of metabolic risk factors such as increased waist circumference, Dyslipidemia, high blood pressure and glucose intolerance. They concluded that Circulating Omentin levels are negatively correlated with the multiplicity of metabolic risk factors, suggesting that Omentin acts as a biomarker of metabolic disorders.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.